Hideki Yasui

Hamamatsu University School of Medicine

Japan

Research Interests

Explore related searches

Professors in Japan

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (25)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2022

Year:

2021

Year:

2020

Year:

2020

Year:

2020

Year:

2020

Year:

2020

Year:

2020

Collaborators (3)

Masahiko Ito

Assistant Professor/Ph.D.

Hamamatsu University School of Medicine

JAPAN

View details

Yuko Tanaka

Hamamatsu University School of Medicine

JAPAN

View details

Yasuaki Mino

Associate Professor・Vice Director

Hamamatsu University School of Medicine

JAPAN

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Hideki Yasui

Research Interests

Explore related searches

Contact this professor

Articles (25)

Depression and its association with mortality in idiopathic pulmonary fibrosis: A real-world data analysis

PAI-1 Inhibitor TM5441 Attenuates Emphysema and Airway Inflammation in a Murine Model of Chronic Obstructive Pulmonary Disease

Quantitative Assessment of Systemic Sclerosis–Related Interstitial Lung Disease via 3D‐Imaging

The role of arterial stiffness as assessed by the cardio-ankle vascular index in patients with chronic obstructive pulmonary disease

Association of interstitial lung abnormalities with cytotoxic agent-induced pneumonitis in patients with malignancy

Association between the HAL score and the development of progressive pulmonary fibrosis in idiopathic interstitial pneumonia: A prospective observational study

Factors associated with uncontrolled severe asthma in the biologic era

Obesity impairs ciliary function and mucociliary clearance in the murine airway epithelium

Olanzapine Plus Triple Antiemetic Therapy for the Prevention of Carboplatin-Induced Nausea and Vomiting: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial

CD109 Attenuates Bleomycin-induced Pulmonary Fibrosis by Inhibiting TGF-β Signaling

Characterization of BRAFThr599dup Mutation as a Targetable Driver Mutation Identified in Lung Adenocarcinoma by Comprehensive Genomic Profiling

Radiological and histopathological features and treatment response by subtypes of interstitial pneumonia with autoimmune features: A prospective, multicentre cohort study

Neutrophil–lymphocyte ratio being associated with mortality risk in patients receiving antifibrotic therapy

“Bull’s-eye” Sign and Its Longitudinal Change on High-Resolution Computed Tomography in Pulmonary Sarcoidosis

Association of constipation with the survival of patients with idiopathic interstitial pneumonias

Geriatric Nutritional Risk Index is a predictor of tolerability of antifibrotic therapy and mortality risk in patients with idiopathic pulmonary fibrosis

Predictors of poor clinical outcomes including in-hospital death and low ability to perform activities of daily living at discharge in hospitalized patients with chronic obstructive pulmonary disease exacerbation

Effect of Hypoxia on Pulmonary Endothelial Cells from Bleomycin-Induced Pulmonary Fibrosis Model Mice

Impact of bronchoalveolar lavage lymphocytosis on the effects of anti-inflammatory therapy in idiopathic non-specific interstitial pneumonia, idiopathic pleuroparenchymal fibroelastosis, and unclassifiable idiopathic interstitial pneumonia

Palliative Care for Idiopathic Pulmonary Fibrosis Patients: Pulmonary Physicians' View

Clinical significance of serum S100 calcium‐binding protein A4 in idiopathic pulmonary fibrosis

Intravoxel incoherent motion magnetic resonance imaging for predicting the long-term efficacy of immune checkpoint inhibitors in patients with non-small-cell lung cancer

Acute exacerbation of unclassifiable idiopathic interstitial pneumonia: comparison with idiopathic pulmonary fibrosis

Prognostic significance of forced vital capacity decline prior to and following antifibrotic therapy in idiopathic pulmonary fibrosis

Pulse oximetric saturation to fraction of inspired oxygen (SpO2/FIO2) ratio 24 hours after high-flow nasal cannula (HFNC) initiation is a good predictor of HFNC therapy in patients with acute exacerbation of interstitial lung disease

Collaborators (3)

Masahiko Ito

Yuko Tanaka

Yasuaki Mino

Make your next move.